A Better Understanding of Moyamoya in Trisomy 21: A Systematic Review

Arowa Abdelgadir 1, Hanna Akram 1, Maurice H. Dick 2, Nabeel R. Ahmed 3, Abanti Chatterjee 4, Sushil Pokhrel 5, Vaishnavi Vijaya Kulkarni 3, Safeera Khan 6

Introduction And Background

Down syndrome is a highly common chromosomal defect in approximately one out of every 800 live births [1]. Down syndrome is primarily caused by chromosome 21 trisomy. Individuals with Down syndrome now have a life expectancy of roughly 60 years [2]. For a variety of reasons, including vascular abnormalities and congenital heart disease, patients with Down syndrome are vulnerable to cerebrovascular accidents. Moyamoya disease is uncommon, progressive stenosis of many cerebral arteries [3]. As a result of this blockage, a vascular network grows around the stenosed vessel. Collaterals are small and delicate vessels that are prone to bleeding, aneurism, or thrombus formation. On standard angiographic imaging, this vascular network appears as a ‘puff of smoke’ (referred to in Japanese as the moyamoya phenomenon) [3]. Moyamoya is classified into two subtypes: idiopathic moyamoya illness and moyamoya syndrome. The vascular alterations in moyamoya syndrome are frequently associated with other syndromes or systemic disorders, examples include Down syndrome, sickle cell anemia, neurofibromatosis type-I, congenital heart disease, fibromuscular dysplasia, activated protein C resistance, and head trauma [4-5]. Moyamoya syndrome in trisomy 21 might manifest clinically as transitory ischemia symptoms or as a neurological disability. Other people may present with no symptoms, and these distinctive vascular alterations may be discovered by chance. Typically, standard angiographic imaging is used to confirm the diagnosis. Moyamoya syndrome in trisomy 21 was poorly understood in terms of its origin and pathophysiology. This comprehensive review attempts to gain a better understanding of the disease’s pathophysiology in Down’s syndrome.

Review

Methods

The findings were reported in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) criteria and principles, and the systematic review was conducted in accordance with...
these standards and principles [6].

Search Strategy

PubMed, PubMed Central (PMC), and Google Scholar were employed as major research literature databases and search engines. The search was conducted utilizing key terms and a medical subject heading (MeSH) method, which might have resulted in the discovery of numerous papers demonstrating a link between moyamoya syndrome and Down syndrome. ‘Down syndrome’ and ‘Moya Moya syndrome’ were the key phrases utilized in the literature search. The MeSH strategy used in PubMed and PMC for the previously listed key words was: (‘Down syndrome/cerebrospinal fluid’ [MeSH] OR ‘Down syndrome/diagnosis’ [MeSH] OR ‘Down syndrome/diagnostic imaging’ [Mesh] OR ‘Down syndrome/etiology’ [MeSH] OR ‘Down syndrome/genetics’ [MeSH] OR ‘Down syndrome/pathology’ [MeSH] OR ‘Down syndrome/physiology’ [MeSH] OR ‘Down syndrome/physiopathology’ [MeSH]) AND (‘moyamoya disease’ [MeSH terms] OR (‘moyamoya’ [All Fields] AND ‘disease’ [All Fields]) OR ‘moyamoya disease’ [All Fields] OR ‘moyamoya’ [All Fields]) OR (idiopathic [All Fields] AND ‘progressive’ [All Fields] AND occlusive [All Fields] AND (‘disease’ [MeSH terms] OR ‘disease’ [All Fields]) AND (‘circle of willis’ [MeSH terms] OR ‘circle’ [All Fields] AND ‘willis’ [All Fields]) OR ‘circle of willis’ [All Fields]) OR (‘moyamoya disease’ [All Fields] OR ‘spontaneous occlusion of the circle of willis’ [All Fields] OR (‘cerebrum’ [MeSH terms] OR ‘cerebrum’ [All Fields] OR ‘cerebral’ [All Fields] OR ‘brain’ [MeSH terms] OR ‘brain’ [All Fields]) AND basal [All Fields] AND rete [All Fields] AND mirabile [All Fields]) OR (‘cerebrum’ [MeSH terms] OR ‘cerebrum’ [All Fields] OR ‘brain’ [MeSH terms] OR ‘brain’ [All Fields]) AND (‘telangiectasis’ [MeSH terms] OR ‘telangiectasis’ [All Fields] OR ‘telangiectasia’ [All Fields]) OR (‘moyamoya disease/blood’ [Majr] OR ‘moyamoya disease/cerebrospinal fluid’ [Majr] OR ‘moyamoya disease/complications’ [Majr] OR ‘moyamoya disease/diagnosis’ [Majr] OR ‘moyamoya disease/diagnostic imaging’ [Majr] OR ‘moyamoya disease/classification’ [Majr] OR ‘moyamoya disease/diagnostic imaging’ [Majr] OR ‘moyamoya disease/genetics’ [Majr] OR ‘moyamoya disease/immunology’ [Majr] OR ‘moyamoya disease/pathology’ [Majr] OR ‘moyamoya disease/physiopathology’ [Majr]).

After the first screening, the total number of papers found in PubMed/Medline was decreased to 393 from 4185. Additionally, a search of the PMC database revealed 12195 papers, which were filtered down to 259. On Google Scholar, approximately 11 papers related to this systematic review were discovered. Additional databases and search engines, such as Cochrane, Web of Science, EBSCO, Popline, and CHBD, did not yield any papers relevant to our inquiry. Grey literature was omitted from this analysis because of the critical need to conduct a validated study.

Eligibility Criteria

The following criteria were used to choose the literature papers that were included in this systematic review:

Inclusion criteria: Papers that have been published within the last 21 years; accepting only full-text papers; patients who exhibit characteristics that are consistent with Down syndrome; findings on imaging suggestive of moyamoya syndrome; symptoms of a stroke ranging from transitory ischemia episodes to permanent neurological impairments; patient with no signs or symptoms of a stroke but a diagnosis of moyamoya syndrome on imaging.

Exclusion criteria: Other causes of cerebrovascular events; papers published more than 21 years ago.

Article Screening and Assess for Eligibility

First, records were screened by title or abstract to weed out those that were deemed unqualified. After that, a set of inclusion and exclusion criteria was used to sort through the remaining data. The remaining articles were read in detail and were checked for quality. The articles that satisfied the quality check were finalized to be included in the review.

PRISMA Flow Diagram

Around 665 items were narrowed down after the initial screening of the identified papers. Approximately 169 duplicate items were eliminated. Then, publications were filtered by title or abstract, and some studies were removed due to a lack of full-text articles and/or irrelevant articles. After evaluating 50 publications for eligibility, only 10 were included in the study.

Figure 1 below depicts the flow diagram for article selection based on PRISMA.
Quality Appraisal of Studies

This systematic review comprised three types of studies: a case report, a case series, and a meta-analysis. The quality of the case reports was assessed using the Joanna Briggs Institute (JBI) check tool, and the quality of the case series was assessed using the National Institutes of Health (NIH) quality assessment tool. A quality assessment was performed using the assessment of multiple systematic reviews (AMSTAR) tool on the meta-analysis study part of this systematic review. This literature review included all articles with a score of 60% or above. The findings are summarized in the following tables (Tables 1-3).
| Study/year of publication | Was the patient's demographic characteristics clearly described? | Was the patient's history clearly described and presented as a timeline? | Was the current clinical condition of the patient on presentation clearly described? | Were diagnostic tests or assessment methods and the results clearly described? | Was the intervention (s) or treatment procedure (s) clearly described? | Was the post-intervention clinical condition clearly described? | Were adverse events (harms) or unanticipated events identified and described? | Does the case report provide takeaway lessons? | Overall appraisal |
|---------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|-----------------------------------------------|-----------------|
| Tajmalzai A et al. 2021[7]| Yes                                                          | Yes                                                          | Yes                                                          | Yes                                           | Un-clear                                      | NA                                            | Yes                                           | Include                             |                 |
| Tavares Bello C et al. 2017[8] | Yes                                                  | Yes                                                          | Yes                                                          | Yes                                           | Yes                                           | Yes                                           | NA                                            | Yes                                           | Include                             |
| Mishra A et al. 2012[9] | Unclear                                                     | Yes                                                          | Yes                                                          | No                                            | No                                            | NA                                            | Yes                                           | Yes                                           | Include                             |
| Roin RA et al. 2008[10]  | Yes                                                          | Yes                                                          | Yes                                                          | Yes                                           | Yes                                           | Yes                                           | NA                                            | Yes                                           | Include                             |
| Lee KY et al. 2013[11]  | Yes                                                          | Yes                                                          | Yes                                                          | Yes                                           | Yes                                           | NA                                            | Yes                                           | Yes                                           | Include                             |
| Sameshima T et al. 2000[12]| Yes                                                      | Yes                                                          | Yes                                                          | Yes                                           | Yes                                           | Yes                                           | NA                                            | Yes                                           | Include                             |
| Makwana M et al. 2017[13]| Yes                                                          | Yes                                                          | Yes                                                          | Yes                                           | Yes                                           | Yes                                           | NA                                            | Yes                                           | Include                             |
| Paneerselvam SP et al. 2019[14]| Yes                                                        | Yes                                                          | Yes                                                          | Yes                                           | No                                            | NA                                            | Yes                                           | Yes                                           | Include                             |

**TABLE 1:** Joanna Briggs Institute (JBI) critical appraisal tool for case reports and case study (2017)

| 1-Was the research topic or goal stated clearly? | Yes |
| 2-Did the study population, including a case definition, have a clear and complete description? | Yes |
| 3-Were the case consequetive? | Yes |
| 4-Did the topics have any parallels? | No |
| 5-Was the intervention clearly described? | Yes |
| 6-Did the outcome measures clearly defined, were they valid, reliable, and used consistently across all study participants? | Yes |
| 7-Was the follow-up period long enough? | Yes |
| 8- Had all statistical procedures been thoroughly described? | Yes |
| 9-Did the results come across as well-written? | Yes |
| 10-How would you rate your overall performance? | Include |

**TABLE 2:** National Institutes of Health (NIH) quality assessment tool for case series
TABLE 3: Assessment of multiple systematic reviews (AMSTAR) assessment tool for meta-analysis

| Study                                                                 | Junqueira PA et al. 2002 [16] |
|----------------------------------------------------------------------|--------------------------------|
| 1-Was the study question clearly described in the publication, and were the inclusion and exclusion criteria listed? | Yes                            |
| 2- Did you conduct a thorough review of the literature?              | Yes                            |
| 3-It should have been chosen by at least two people?                 | Yes                            |
| 4-Was the publication's status used as a factor for inclusion?       | No                             |
| 5- Were there at least two participants who were not included in the study? | Can't say                      |
| 6-Was the study that was excluded listed?                           | No                             |
| 7-Did the relevant characteristics of the studies that were included in the analysis be provided? | Yes                            |
| 8-Was the scientific quality of the research included in the review evaluated and reported? | Yes                            |
| 9-Was the scientific quality of the studies included in the analysis adequately used? | Yes                            |
| 10-Did the right Methods for combining the findings of each particular study? | Yes                            |
| 11-Was the likelihood of publication bias properly assessed?         | Yes                            |
| 12-Was there a declaration of a conflict of interest?                | Yes                            |
| 13-Overall evaluation                                               | Include                        |
| 14-Do the findings of this study apply directly to the patient population targeted by this guideline? | Yes                            |

Results

Two independent authors extracted data from the finalized studies for this systematic review. The previous studies identified a total of 54 cases and recorded the following clinical and epidemiological data (Tables 4-9).

| Gender                          |
|--------------------------------|
| Gender                         |
| 23 males (42.59%)              |
| 31 females (57.40%)            |

TABLE 4: Gender

| Age of the patients included in this systematic review | The total number of patients | Percentage |
|-------------------------------------------------------|------------------------------|------------|
| Grouping by age                                       |                              |            |
| Up to the age of 12                                   | 44                           | 81.48%     |
| 13–19 years of age                                    | 3                            | 5.55%      |
| Over the age of 20                                    | 7                            | 12.96%     |

TABLE 5: Age range of participants in this systematic review
Clinical manifestations

| Symptoms                        | Symptoms reported by patients | Percentage |
|---------------------------------|-------------------------------|------------|
| Hemiparesis                     | 42                            | 77.77%     |
| Speech disorder                 | 12                            | 22.22%     |
| Seizure                         | 9                             | 16.66%     |
| Involuntary movement            | 3                             | 5.55%      |
| Facial Paralysis                | 6                             | 11.11%     |
| Headache                        | 3                             | 6.55%      |
| Optic atrophy and cortical blindness | 1                      | 1.85%      |
| Altered Sensorium               | 1                             | 1.85%      |
| Hemihypersethia                 | 1                             | 1.85%      |
| Estropia, amblyopia, Cyclotorsion of eyes, Horizontal nystagmus | 1 | 1.85% |
| Urinary Incontinence            | 1                             | 1.85%      |

**TABLE 6: Clinical presentation**

| Presentational subtype                      | Number of the patients | percentage |
|---------------------------------------------|------------------------|------------|
| Ischemic Stroke                             | 42                     | 77.77%     |
| Transient ischemic attacks                  | 8                      | 14.81%     |
| Hemorrhagic Stroke                          | 4                      | 7.40%      |
| Intracerebral Haematoma with Intraventricular Extension | 1                      | 1.85%      |
| Recurrent ischemic episode                  | 30                     | 55.55%     |
| Isolated Ischemic Episode                   | 21                     | 38.88%     |

**TABLE 7: Presentational subtype**

| Involvement of the vascular system           | Number of the patients | percentage |
|----------------------------------------------|------------------------|------------|
| Bilateral                                    | 41                     | 75.92%     |
| Unilateral                                   | 9                      | 16.66%     |
| Not identified                               | 4                      | 7.40%      |

**TABLE 8: Involvement of the vascular system**
Evaluation of cardiac abnormalities

| the nature of the cardiac abnormality | Number of the patients | percentage |
|--------------------------------------|------------------------|------------|
| Congenital heart disease             | 12                     | 22.22%     |
| Normal heart                         | 2                      | 3.70%      |
| Not identified                        | 40                     | 74.07%     |

TABLE 9: The type of cardiac anomaly discovered in the participants included in this systematic review

The majority of the instances featured in this research were in females and occurred in the first decade. Ischemic stroke is more common in the first decade of life, although the clinical picture changes as people get older. Hemorrhagic stroke is the most common type of stroke in adults. Moyamoya phenomena were found in all the angiography instances that were described. Many possibilities have been put up as to why moyamoya syndrome is linked to trisomy 21, and these will be investigated in greater depth later in this study. Understanding the pathophysiology of moyamoya syndrome in Down syndrome patients will aid in the treatment and prevention of recurrence of symptoms.

Discussion

A condition called moyamoya disease can rarely result in gradual worsening stenosis of one’s internal carotid artery or the anterior, middle, or posterior cerebral arteries. An arterial network is formed around the site of stenosis to compensate, and this phenomenon is called the moyamoya phenomenon in Japanese. The syndrome was first described in Japanese patients, and its frequency is still very high in Japan, affecting roughly five out of 100,000 people. Moyamoya syndrome is characterized by vascular abnormalities that occur in conjunction with other systemic diseases or syndromes, such as thyrotoxicosis, leptospirosis, tuberculosis, aplastic anemia, Fanconi anemia, sickle cell anemia, lupus anticoagulant or antiphospholipid, Down syndrome, Marfan syndrome, tuberous sclerosis, Turner syndrome, and coarctation of the aorta. A greater proportion of Asians are infected with moyamoya illness. Females are nearly twice as likely as males to suffer from the condition. Among those with Down syndrome, moyamoya illness is three times more common than in the general population [17-18]. It is not clear why this is the case. Most patients present in the first decade with a smaller percentage appearing in the fourth decade [19-20]. It is a bilateral disease; however, there has been an increase in cases where just one side is affected.

Etiology and Pathology of Moyamoya in Trisomy 13

Inflammation or atherosclerosis was not found in the stenosed arteries. Smooth muscle hypertrophy, luminal thrombosis, and tunica media thinning are all observed in these stenosed arteries. When blood flow is raised because of the obstruction, a compensatory network of vascular vessels forms composed of both pre-existing and newly formed vessels, this suggests that the increased blood flow has stressed the vessels. The observed modifications are fragmented elastic lamina, thinning media, and microaneurysms. The underlying mechanism of moyamoya disease in trisomy 21 has been the subject of several hypotheses. There has been some discussion of a genetic cause for this connection. There is an increase in the expression of certain growth factors, enzymes, and peptides in patients with moyamoya illness. Some of these growth factors are transforming growth factor-1, hepatocyte growth factor, vascular endothelial growth factor, and hypoxia-inducing factor-1 [21].

When it comes to blood vessels, people with Down syndrome are genetically predisposed to developing a wide range of anomalies, from an irregular nail bed capillary structure to pulmonary artery hypertension to retinal vessel abnormalities to renal artery hypertension [22]. Many proteins on chromosome 21 have an impact on arterial physiology and flexibility. Several proteins are implicated in oxidative stress, including superoxide dismutase-1, interferon-gamma receptor, and cystathionine synthase [23]. The low rate of atheroma in Down syndrome patients may be caused by one or more of these proteins [24-26]. Collagen type VI was found in the lining of large arteries. Vascular injury may boost its expression in cerebral arteries [27]. The alpha-chain collagen is encoded on chromosome 21. As a result, aberrant overexpression of collagen type VI in some cases of moyamoya syndrome may result in malformed blood vessels [28].

The RNF213 protein gene is frequently mutated in patients with moyamoya. The development of blood vessels is aided by this protein, which is found throughout the body. There are two distinct protein ‘classes,’ and RNF213 is a member of both. To begin with, it is an E3 enzyme in nature. This protein can identify undesired or malfunctioning proteins, and the cell can then be rid of them. A motor protein is also present. Small molecular ‘engines’ that transform chemical energy into movement are found in motor proteins. Only
the human protein RNF213 performs both of these tasks. In biochemical studies of the mutation most commonly observed in moyamoya patients, the overall structure, ATPase motor, and E3 module of RNF213 were all confirmed to be intact. Therefore, the disease-causing mutation appeared to affect interactions with other companion proteins rather than destroying RNF213 itself \cite{29}. Nevertheless, an interaction between RNF213 and genes on chromosome 21 may result in moyamoya syndrome in persons with Down syndrome.

**Histopathological Findings**

There is an uneven elastic lamina in the sick vessel, surrounded by areas of significant endothelial hyperplasia, fibrous intimal thickening, tunica media with atrophic zones replaced by collagen, and damaged and thickened elastic layer \cite{30}.

**Clinical Presentation and Diagnosis**

Moyamoya syndrome clinical manifestations in Down syndrome patients vary with age. Ischemic stroke or transient ischemic episodes are more common in children at a higher risk of hemorrhagic stroke as they age. Symptoms include headache, involuntary movement, difficulty speaking, weakness in the arms and/or legs, cognitive impairment, and seizure. To confirm the diagnosis, the following criteria must be met:

(a) Stenosis of the distal intracranial portion of the internal carotid artery, or the proximal anterior cerebral artery, middle, or posterior cerebral artery.

(b) An abnormal vascular network developing near the stenosis from the thalamoperforate and lenticulostriate arteries.

(c) Rule out other possible causes, such as trauma, meningitis, sickle cell disease, tumors, or radiation therapy.

Cerebral angiography confirms the diagnosis by showing the distinct collateral development along the stenotic artery.

**Treatment Options of Moyamoya Disease**

Management of moyamoya syndrome is controversial. Some clinicians support medical treatment only, while others prefer the long-lasting protecting outcome of surgery.

The treatment options are divided into medical and surgical. Medical management includes aspirin. At the same time, the surgical intervention involves several revascularization procedures. These are encephaloarteriosynangiosis, encephalomyosynangiosis, superficial temporal artery to middle cerebral artery anastomosis, and omental transplantation. Cerebral revascularization surgery with the pial synangiosis technique provides a better outcome with reduced future risk of stroke compared to other techniques \cite{31-34}. There is no rule for anticoagulant medication in secondary prevention as the risk of bleeding in these patients is high.

**Limitations**

The limitation of this systematic review was the limited number of studies examining the underlying mechanism of moyamoya syndrome. Additionally, the majority of the papers discovered were case reports. In addition, some patients were followed for a short period of time, while others were difficult to track down for an extended period of time.

**Conclusions**

The association of moyamoya syndrome with trisomy 21 has been increasingly recognized over the last few years. The reason for this association is yet to be understood, with many hypotheses, most of them pointing toward genetic predisposition linking moyamoya syndrome and trisomy 21. The RNF213 gene may interact with the genes on chromosome 21 that influence vascular physiology and elasticity in patients with Down syndrome, resulting in the picture of moyamoya syndrome. Further research is needed to confirm or rule out this association. In patients with Down syndrome who present with neurological deficits, a diagnosis of moyamoya syndrome should always be kept in mind, and the diagnosis should be confirmed with cerebral angiographic studies.

**Additional Information**

**Disclosures**

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from
any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. eMedicine: Down syndrome. (2021). Accessed: September 15, 2021: http://emedicine.medscape.com/article/945216-overview.

2. Glasson EJ, Sullivan SG, Hussain R, Pettersson BA, Montgomery PD, Bittles AH: The changing survival profile of people with Down’s syndrome: implications for genetic counselling. Clin Genet. 2002, 62:390-3. 10.1034/j.1399-0004.2002.620506.x

3. Scott RM, Smith ER: Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009, 360:1226-37. 10.1056/NEJMra0804657

4. Árêvalo CE, Marchezottti A, Haesler A, Lanosa R: Moyamoya disease and Down syndrome [Article in Spanish]. Medicina (B Aires). 1995, 55:473.

5. Wanifuchi H, Kagawa M, Takeshita M, Izawa M, Maruyama S, Kitamura K: Autoimmune antibody in moyamoya disease [Article in Japanese]. No Shinkei Geka. 1986, 14:51-5.

6. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136/bmj.n71

7. Tajimatzu A, Shirzai A, Najah DM: Early manifestation of moyamoya syndrome in a 2-year-old child with Down syndrome. Radiol Case Rep. 2021, 16:1740-4. 10.1016/j.radcr.2021.04.017

8. Tavares Bello C, Barreiros C, Gil I, Vasconcelos C: Down syndrome and moyamoya disease: unusual cause of stroke. BMJ Case Rep. 2017, 2017: 10.1136/br-2017-219894

9. Mishra A, Pendharkar H, Jayadasevan ER, Bodhey N: Anomalous origins of bilateral vertebral arteries in a child with Down syndrome and Moyamoya disease. A case report. Interv Neuroradiol. 2012, 18:259-63. 10.1177/194191071201800305

10. Rison RA: Fluctuating hemiparesis secondary to moyamoya phenomenon in a child with Down syndrome: a case report. Cases J. 2008, 1:240. 10.1186/1757-1626-1-240

11. Lee KY, Lee KS, Weon YC: Asymptomatic moyamoya syndrome, atlantoaxial subluxation and basilar ganglia calcification in a child with Down syndrome. Korean J Pediatr. 2013, 56:540-5. 10.3345/kjp.2013.56.12.540

12. Samegishi T, Morita Y, Yangita M, Nakano S, Goya T, Wakisaka S: Unilateral middle cerebral artery stenosis in an adult with Down’s syndrome. Neurol Med Chir (Tokyo). 2000, 40:216-9. 10.2176/nmc.40.216

13. Maksmana W, Vishnoi RK, Soni JP, Jetha K, Verma SK, Choudhary PS, Choudhary M: Moyamoya disease and Down syndrome. J Evol Med Healthc. 2012, 6:1735-1737.

14. Paneerselvam SP: Rare case of Down syndrome with stroke-moyamoya. Univ J Med Spec. 2019, 5: 10.4103/jpn.JPN_116_17

15. Kumar P, Pandirali I, Sanbhyan M, Ajuha C, Goyaki PK: Down syndrome with moyamoya disease: a case series. J Pediatr Neurosci. 2018, 13:201-4. 10.1016/j.jpn.2018.09.001

16. Junqueira PA, Moura-Ribeiro MV: Moyamoya and Down syndrome: study conducted by meta-analysis [Article in Portuguese]. Arq Neuropsiquiatr. 2002, 60:274-80.

17. Ajimi Y, Uchida K, Kawase T, Toya S: A case of Turner’s syndrome associated with moyamoya disease [Article in Japanese]. No Shinkei Geka. 1992, 20:1021-4.

18. Fukui M: Current state of study on moyamoya disease in Japan. Surg Neurol. 1997, 47:138-43. 10.1016/S0387-7604(12)80239-7

19. de Borchgrave V, Sauxu F, Deppe A, de Barsy T: Moyamoya disease and Down syndrome: case report and review of the literature. Acta Neurol Belg. 2002, 102:63-6.

20. Abel J, Lehner A, Vogel A, Schleiffer A, Meinhart A, Haselbach D, Clausen T: Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism. eLife. 2020, 9:e56185. 10.7554/eLife.56185

21. Cramer SC, Robertson RL, Dooling EC, Scott RM: Moyamoya and Down syndrome: clinical and radiological features. Stroke. 1996, 27:2131-5. 10.1161/01.str.27.11.2131

22. Suzuki J, Takaku A: Cerebrovascular moyamoya disease: disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969, 20:288-99. 10.1001/archneur.1969.00480090076012

23. Fung CW, Kwong KL, Tsui EY, Wong SN: Moyamoya and Down syndrome [Article in Japanese]. No Shinkei Geka. 1986, 14:31-5.

24. Korenberg JR: Toward a molecular understanding of Down syndrome. Prog Clin Biol Res. 1993, 384:87-115.

25. Nordström M, Kjellström T: Age dependency of cystathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis. 1992, 94:215-21. 10.1016/0021-9150(92)90244-d

26. Hansson GK, Holm J: Interferon-gamma inhibits arterial stenosis after injury. Circulation. 1991, 84:1266-72. 10.1161/01.cir.84.3.1266

27. Park JW, Braun P, Mertens S, Heinrich KW: Ischaemia: reperfusion injury and restenosis after coronary angioplasty. Ann N Y Acad Sci. 1992, 669:215-36. 10.1111/j.1749-6632.1992.tb17102.x

28. Hesle H, Engvall E: Type VI collagen. Studies on its localization, structure, and biosynthetic form with monoclonal antibodies. J Biol Chem. 1984, 259:5955-61.

29. Healthjade: moyamoya disease. (2018). Accessed: September 15, 2021: https://healthjade.net/moyamoya-disease/

30. Nagasaki T, Shiozawa Z, Kobayashi M, Shindo K, Tsunoda S, Amino A: Autopsy findings in Down’s syndrome with cerebrovascular disorder. Clin Neuropathol. 1996, 15:145-9.

31. Mito T, Becker LE: Vascular dysplasia in Down syndrome: a possible relationship to moyamoya disease. Brain Dev. 1992, 14:248-51. 10.1016/0387-7604(92)90239-7

32. Gaggero R, Donati PT, Curia R, De Negri M: Occlusion of unilateral carotid artery in Down syndrome. Brain Dev. 1996, 18:81-3. 10.1016/0387-7604(95)00114-x

33. Matsuhashi T, Inoue T, Suzuki SO, Fujik K, Fukui M, Hasu K: Surgical treatment of moyamoya disease in
pediatric patients—comparison between the results of indirect and direct revascularization procedures. Neurosurgery. 1992, 31:401-5. 10.1227/00006123-199209000-00003

34. Jea A, Smith ER, Robertson R, Scott RM: Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization. Pediatrics. 2005, 116:e694-701. 10.1542/peds.2005-0568